by Suzannah Cavanaugh | Oct 30, 2020
In the Covid-19 vaccine race, Moderna, Inc. made headlines last week for the representative diversity of its trial candidates. The company touted 37% enrollment by people of color in late-stage trials, a figure that nearly mirrors the 40% of the population U.S....
by Suzannah Cavanaugh | Oct 2, 2020
Moderna Inc. announced Tuesday that its Covid-19 vaccine candidate had generated levels of virus-neutralizing antibodies in older adults on par with those produced in younger trial participants, a crucial step towards approval. The early-stage result gives Moderna a...
